Skin Cancer Clinical Trial
Official title:
TLR4 Polymorphisms and Predisposition for Skin Cancer Development
Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptor-4 (TLR4) in particular, appears to play a role in susceptibility to cancer. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene. Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer.
Toll-like receptors (TLRs) play a key role in the innate immune system. Toll-like receptors generally, and TLR4 in particular, appear to play a role in cancer susceptibility as well as tumor immunosuppression and stromal invasion. Of 44 identified SNPs (small nucleotide polymorphisms) in TLR4, the most common is an A-G substitution at nucleotide position +896, downstream of the cDNA start codon, a missense mutation which leads to an amino acid substitution Asp299Gly in the third exon of the TLR4 gene, and which was later shown to co-segregate with SNP Thr399Ile-also in the third exon of TLR4.1 This SNP, present in 10% of the general population, has been found associated with gastric cancer, prostate cancer, and nasopharyngeal cancer.2-4 Pre-clinical studies from our laboratory have shown an association of TLR4 with ultraviolet radiation induced skin cancer. Hence, in this study we will assess the pattern of TLR4 polymorphisms and susceptibility to skin cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
| Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
| Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
| Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
| Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
| Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
| Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
| Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
| Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
| Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
| Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
| Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
| Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
| Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
| Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
| Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
| Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |